VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
Cancer pain managment
1. Dr. Md Mamun ur Rashid
DA , FCPS (ANAESTHESIA)
FIPM(Delhi)
2. CANCER PAIN : PREVALENCE &IMPACT
More than 14 million cases of cancer were diagnosed
worldwide
1 in 3 patients on average do not receive adequate
pain medication
50% of patients undergoing treatment for cancer and
up to 90% of patients with advanced cancer have pain
Cancer pain is multi focal, multi causal & dynamic.
Most patients have more than one type of pain
3. Barriers to effective pain
management
lack of knowledge regarding pain
assessment and management
• misconceptions about the analgesic use
• Increased survival among persons with
cancer due to introduction of new
treatments
• govt restrictions on sale of opioids
• opiophobia
4. CLASSIFICATION OF
CANCER PAIN
1. Somatic : bone metastasis
2. Visceral : pancreatic carcinoma
3. Neuropathic : plexopathy
4. Sympathetically maintained pain :
reflex sympathetic dystrophy
5. Pain is a cornerstone of
cancer treatment:
• promotes an enhanced quality of life
• Avoids psychological effects of cancer
pain
• improves functioning
• means for patients to focus on their
lives
• Increased survival
6. CAUSES OF PAIN IN CANCER
1. Tumor infilteration
2. Involvement of nerves/plexus
3. Bony mets
4. Massive ascites, pleural effusion
5. Visceral and peritoneal infilteration
6. Related to cancer treatment –
mucosites, polyneuropathy,
Postsurgical chronic pain syndromes
7. ASSESSMENT OF PAIN INTENSITY
Pain evaluation includes a detailed
oncologic, medical & psychosocial
assessment
Wisconsin Brief Pain Inventory (BPI)
Memorial Pain Assessment Card
Edmonton Staging System
Numerical Pain Rating Scale or VAS
WHO QOL scores
Eastern cooperative oncology group
performance scale & Karnofsky rating
8. Continue
Pediatric cancer pain assessment
includes use of the Beyer Oucher, Eland
Color Scale-Body Outline, Hester Poker
Chip Tool, and McGrath Faces Scale
The BPI is a 15-minute questionnaire
that can be self-administered.
It incorporates two valuable features of
the McGill Pain Questionnaire—a
graphic representation of the location of
pain and groups of qualitative descriptors
9.
10. EVALUATION OF THE PATIENT WITH
CANCER PAIN
1. Oncologic history
• diagnosis and stage of disease
• History of implemented therapies -
chemotherapeutic agents used, types of
surgery, site of therapy
• radiotherapy
• outcome (including side effects)
• patient’s understanding of the disease
process and prognosis
11. Continue
2. Pain history
for each new pain site-
• Onset and evolution
• site and radiation areas
• Pattern (constant, intermittent, or
unpredictable)
• Intensity (best, worst, average, current;
rating on a 0 to 10 scale)
• quality, exacerbating and relieving factors
• pain interference with usual activities
• neurologic and motor abnormalities
(including bowel and bladder continence)
12. Continue
◦ vasomotor changes
• Current and past analgesics (use, efficacy, side
effects)
• Prior analgesic use, efficacy, and side effects
3.Psychosocial history
4. Medical history (independent of oncologic history)
• coexisting systemic disease
• Exercise intolerance
• allergies to medications
• current medications
• prior illness and surgery
5. Physical Examination
The physical examination must be thorough
13. MANAGEMENT OF CANCER-
RELATED PAIN
Basic principle :
• modifying its source (treatment of
cancer)
• interrupting its transmission
• modulating its influence at brain or
spinal cord sites (analgesics, anti
depressants, anxiolytics, neuraxial
analgesia)
14. GUIDELINES FOR CANCER PAIN
MANAGEMENT
1. WHO analgesic ladder
2. Pain treatment cantinuum
17. Continue
ADVANTAGE:
Effective pain relief
70-80% patients
Simple to use
assessment of cancer
pain
DISADVANTAGE:
less emphasis on
regional blocks
Extra emphasis on
opioids, not easily
available especially
oral morphine
18. Continue
The most effective form of treatment of any
cancer related pain is treatment of the cancer
itself
More than one treatment modality can be
employed at one time and one modality can
supersede another according to patients need
22. Pharmacologic Management
Oral analgesics are the mainstay of
therapy for patients with cancer pain
The noninvasive route should be
maintained as long as possible
1. Paracetamol & NSAIDS
blocks synthesis of prostaglandins,
which activates nociceptive fibres
Mild pain
Opioid sparing
Less side effects
24. Continue
3. Opioids
1st line for moderate to severe cancer pain
Effective pain control in 85% patients
Easily titrable
Good risk benefit ratio.
Dosage
1. Morphine 10mg; q 3-4h (max 400mg/d) GOLD
STANDARD FOR MOD-SEVERE PAIN
2. Codeine 120-360 mg; q 3-4h
25. Continue
3.Tapentadol 100-400mg/day NEW SYNTHETIC
OPIOID FOR SEVERE CANCER PAIN & LESSER
SIDE EFFECT
4.Tramadol 50-100mg; q8-12h(max 400mg/d)
5.Transdermal Fentanyl & transdermal
Buprenorphine.
Opioid responsiveness : it is the probability of
adequate analgesia(satisfactory without
intolerable & unmanageable side effects) that
can be attained during gradual dose titration
30. Continue
2. ANTI DEPRESSANTS
For neuropathic pain
Potentiate analgesic properties of opioids
31. Continue
3. CORTICOSTEROIDS
Mechanism:
• Reduction of inflammation
• Block C-fiber transmission
• Weak local anesth properties
• Reduce ectopic discharge from neuromas
• Action on dorsal horn cells
32. Continue
4. Neuron Revitalizer :
Methoxycobalamine: 500mcg TDS neuron
regeneration
5. Muscle Relaxants:
For muscle spasm
Tizanidine 2-6mg TDS
6. BISPHOSPHONATES
used in multiple myelomas, bone mets
7. OSTEOCLAST INHIBITORS
neuropathic & bone pain
33. Interventional Techniques for
Pain Management
When pharmacologic therapy fails to
provide adequate analgesia or leads to
unacceptable side effects.
A. Intravenous Infusion of Opioids with
Patient-Controlled Analgesia Devices
Indications
• severe pain
• need to titrate opioids rapidly
• oral route is not available because of
gastrointestinal (GI) obstruction,
malabsorption, uncontrolled nausea and
vomiting, dysphagia.
34. Continue
B. Intraspinal Analgesia
Used when :
1. Systemic opioids provides pain relief but
with unacceptable side effects
2. Unsuccessful treatment with strong
opioids
3. Life expectancy > 3-6mnths opioid alone
or in combination with other agents such as
bupivacaine, clonidine(30-120mcg/day),
midazolam(1.2mg/day
35. Continue
4.Intraspinal morphine is GOLD STANDARD
therapy (0.5 mg/day to 12.5mg/day)
5. pain relief is in a highly selective fashion
without motor, sensory, and sympathetic
effects
6. analgesia was potentially superior to that
achieved when opioids were administered
by other routes and, because the total
amount of drug administered is reduced,
side effects are minimal
36. Continue
C. NEUROLYTIC BLOCKS
SOMATIC & SENSORY BLOCKS:
• Paravertebral block: CA lung, Rib
secondaries
• Intercostal nerve block : CA breast, rib
seconadries
• Mandibular & Maxillary nerve block : CA
cheek, salivary gland tumor
• Deep & superficial cervical blocks: nerve
tumors, thyroid CA.
37. Continue
SYMPATHETIC PLEXUS BLOCK:
• Stellate ganglion block: upper limb tumors
• Coeliac plexus block: CA liver, pancrease,
stomach
• Lumbar plexus block: pelvic & lower limb CA
• Superior hypogastric plexus block: pelvic CA,
cervix, body of uterus
• Ganglion Impar block: CA rectum
38. Continue
Limitations :
• New pathways develop
• Pain relief upto 60-70%
• Duration 3-4mnths
• Deafferentation pain synd
Morbidity of procedure
D. INTRAVENOUS LIGNOCAINE INFUSION:
central analgesia, 5mg/kg over 60mins
upto 3weeks